TY - JOUR
T1 - Development and validation of a high performance liquid chromatography method to determine linezolid concentrations in pig pulmonary tissue
AU - Guerrero, Laura
AU - Martínez-Olondris, Pilar
AU - Rigol, Montserrat
AU - Esperatti, Mariano
AU - Esquinas, Cristina
AU - Luque, Néstor
AU - Piñer, Raquel
AU - Torres, Antoni
AU - Soy, Dolors
N1 - Funding Information:
there are no conflicts of interest regarding the publication of this article. Research funding played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication. Research funding: This study was funded by grants from Ciber de Enfermedades Respiratorioas (CibeRes, CB06/06/0028) from Insti-tuto de Salud Carlos III (ISCIII), Fondo de Investigaciones Sani-tarias (FIS) beca FIS PI070419, 2009 SGR-911 and HERACLES RD /06/0009/0008. Employment or leadership: None declared. Honorarium: None declared.
PY - 2010/3/1
Y1 - 2010/3/1
N2 - Background: Linezolid is the first synthetic compound of a new group of antimicrobials, the oxazolidinones, which inhibit protein synthesis. It shows a broad spectrum of activity against Gram positive organisms. With respect to its pharmacokinetics, linezolid shows a relatively high volume of distribution and good penetration into inflammatory fluids, bone, fat and muscle. Methods: A reversed-phase isocratic high-performance liquid chromatographic method for linezolid analysis in piglet pulmonary tissue is described. Tissue samples and controls were prepared in 1×TBE (1 M Tris, 0.9 M boric acid, 0.01 M EDTA). The mobile phase consisted of 20% ultrafiltered water and 80% of (A) 15 mM potassium monohydrogen phosphate buffer (pH=5) with (B) acetonitrile (80%/20%; v/v). Samples were homogenized and precipitated with HClO4 3% (1/1, v/v). The injection volume was 100 μL. Ofloxacin was used as an internal standard. Results: The assay was linear over a linezolid concentration range: 1.6-100 μg/mL. The method provided good validation data (n=15): inaccuracy (3.6%), intra and inter-day variability (4.2% and 5.2%, respectively), recovery (91.8%), limit of detection (0.8 μg/mL) and quantitation (1.6 μg/mL) and acceptable stability within 24 h in the auto-sampler. Conclusions: The method offers a fast and simple approach to determine linezolid in pulmonary tissue which could be of use in pharmacokinetic studies.
AB - Background: Linezolid is the first synthetic compound of a new group of antimicrobials, the oxazolidinones, which inhibit protein synthesis. It shows a broad spectrum of activity against Gram positive organisms. With respect to its pharmacokinetics, linezolid shows a relatively high volume of distribution and good penetration into inflammatory fluids, bone, fat and muscle. Methods: A reversed-phase isocratic high-performance liquid chromatographic method for linezolid analysis in piglet pulmonary tissue is described. Tissue samples and controls were prepared in 1×TBE (1 M Tris, 0.9 M boric acid, 0.01 M EDTA). The mobile phase consisted of 20% ultrafiltered water and 80% of (A) 15 mM potassium monohydrogen phosphate buffer (pH=5) with (B) acetonitrile (80%/20%; v/v). Samples were homogenized and precipitated with HClO4 3% (1/1, v/v). The injection volume was 100 μL. Ofloxacin was used as an internal standard. Results: The assay was linear over a linezolid concentration range: 1.6-100 μg/mL. The method provided good validation data (n=15): inaccuracy (3.6%), intra and inter-day variability (4.2% and 5.2%, respectively), recovery (91.8%), limit of detection (0.8 μg/mL) and quantitation (1.6 μg/mL) and acceptable stability within 24 h in the auto-sampler. Conclusions: The method offers a fast and simple approach to determine linezolid in pulmonary tissue which could be of use in pharmacokinetic studies.
KW - Analytics
KW - Chromatography
KW - High pressure liquid
KW - Linezolid
KW - Tissue
KW - Validation
UR - http://www.scopus.com/inward/record.url?scp=77249155244&partnerID=8YFLogxK
U2 - 10.1515/CCLM.2010.078
DO - 10.1515/CCLM.2010.078
M3 - Article
C2 - 20113250
AN - SCOPUS:77249155244
SN - 1434-6621
VL - 48
SP - 391
EP - 398
JO - Clinical Chemistry and Laboratory Medicine
JF - Clinical Chemistry and Laboratory Medicine
IS - 3
ER -